[1] Llovet, J. M., Burroughs, A., and Bruix, J. (2003). Hepatocellular carcinoma. Lancet, 362, 1907-1917.
[2] Llovet, J. M., and Beaugrand, M. (2003). Hepatocellular carcinoma:present status and future prospects. J Hepatol, 38, 136-149.
[3] McGlynn, K. A., Tsao, L., Hsing, A. W., Devesa, S. S., and Fraumeni, J. F. J. (2001). International trends and patterns of primary liver cancer. Int J Cancer, 94, 290-296.
[4] Seow, T. K., Liang, R. C., Leow, C. K., and Chung, M. C. (2001). Hepatocellular carcinoma,From bedside to proteomics. Proteomics, 1, 1249-1263.
[5] Thorgeirsson, S. S., and Grisham, J. W. (2002). Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet, 31, 339-346.
[6] Leung, T. W., Patt, Y. Z., Lau, W. Y., Ho, S. K., Yu, S. C., et al. (1999). Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma. Clin Cancer Res, 5, 1676-1681.
[7] Poon, R. T., Fan, S. T., Lo, C. M., Liu, C. L., and Wong, J. (1999). Intrahepatic recurrence after curative resection of hepatocellular carcinoma, long term results of treatment and prognostic factors. Ann Surg, 229, 216 -222.
[8] Lowe, S. W., and Lin, A. W. (2000). Apoptosis in cancer. Carcinogenesis, 21, 485- 495.
[9] Hengartner, M. O. (2000). The biochemistry of apoptosis. Nature, 407, 770-776.
[10] Ghobrial, I. M., Witzig, T. E., and Adjei, A. A. (2005) Targeting apoptosis pathways in cancer therapy. CA Cancer J Clin, 55, 178-194.
[11] Denicourt, C., and Dowdy, S. F. (2004). Targeting apoptotic pathway in cancer cells. Science, 305, 1411-1413.
[12] Yim, E. K., Lee, K. H., Namkoong, S. E., Um, S. J., and Park, J. S. (2006). Proteomic analysis of ursolic acid-induced apoptosis in cervical carcinoma cell. Cancer lett, 235, 209-220.
[13] Neo, J. C., Rose, P., Ong, C. N., and Chung, M. C. (2005). beta- Phenylethyl isothiocyanate mediated apoptosis, A proteomic investigation of early apoptotic protein changes. Proteomics, 5, 1075- 1082.
[14] Dong, H., Ying, T., Li, T., Cao, T., Wang, J., et al. (2006). Comparative Proteomic Analysis of Apoptosis Induced by Sodium Selenite in Human Acute Promyelocytic Leukemia NB4 Cells. Journal of Cellular Biochemistry, 98, 1495-1506.
[15] Monge, M., Vilaseca, M., Soto-Cerrato, V., Montaner, B., Giralt, E., and Perez-Tomas, R. (2007). Proteomic analysis of prodigiosin-induced apoptosis in a breast cancer mitoxantrone-resistant MCF-7 MR cell line. Invest New Drugs, 25, 21-29.
[16] Prince, P., and Mcmillan, T. J. (1990). Use of the tetrazolium assay in measuring the response of human tumor cells to ionizing radiation. Cancer Res, 50, 1392-1396.
[17] Yu, L. R., Zeng, R., Shao, X. X., Wang, N., Xu, Y. H., and Xia, Q. C. (2000). Identification of differentially expressed proteins between human hepatoma and normal liver cell lines by two-dimensional electrophoresis and liquid chromatography-ion trap mass spectrometry. Electrophoresis, 21, 3058-3068.
[18] Ding, S. J., Li, Y., Shao, X. X., Zhou, H., Zeng, R., et al. (2004). Proteome analysis of hepatocellular carcinoma cell strains, MHCC97-H and MHCC97-L, with different metastasis potentials. Proteomics, 4, 982-994.
[19] Yokoo, H., Kondo, T., Fujii, K., Yamada, T., Todo, S., and Hirohashi, S. (2004). Proteomic signature corresponding to alpha fetoprotein expression in liver Cancer cells. Hepatology, 40, 609-617.
[20] Ding, S. J., Li, Y., Tan, Y. X., Jiang, M. R., Tian, B., et al. (2004). From proteomic analysis to clinical significance, overexpression of cytokeratin 19 correlates with hepatocellular carcinoma metastasis. Mol Cell Proteomics, 3, 73-81.
[21] Ramagli, L. S. (1999). 2-D Proteome Analysis Protocols, Humana Press, Totowa, NJ, USA 99-103.
[22] Liang, R. C., Neo, J. C., Lo, S. L., Tan, G. S., Seow, T. K., and Chung, M. C. (2002). Proteome database of hepatocellular carcinoma. J Chromatogr B Analyt Technol biomed Life Sci, 771, 202-228.
[23] Neuhooff, V., Arold, N., Taube, D., and Ehrhardt, W. (1988). Improved staining of proteins in polyacrylamide gels including isoelectric focusing gels with clear background at nanogram sensitivity using Coomassie Brilliant Blue G-250 and R-250. Electrophoresis, 9, 255-62.
[24] Oertel, J., and Huhn, J. (2000). Immunocytochemical methods in haematology and oncology. J Cancer Res Clin Oncol, 126, 425-440.
[25] Venter, J. C., Adams, M. D., Myers, E. W., Li, P. W., Mural, R. J., et al. (2001). The sequence of human genome. Science, 291, 1304-1351.
[26] Strausberg, R. L., Feingold, E. A., Grouse, L. H., Derge, J. G., Klausner, R. D., et al. (2002). Generation and initial analysis of more than 15000 full-length human and mouse cDNA sequences. Proc Natl Acad Sci, 99, 16899-16903.
[27] Ambrosini, G., Adida, C., and Altieri, D. C. (1997). A noval antiapoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med, 3, 917-921.
[28] Vilana, R., Bruix, J., Bru, C., Ayuso, C., Sole, M., and Rodes, J. (1992). Tumor size determines the efficacy of percutaneous ethanol injection for the treatment of small hepatocellular carcinoma. Hepatology, 16, 353- 357.
[29] Shiina, S., Tagawa, K., Niwa, Y., Unuma, T., Komatsu, Y., et al. (1993). Percutaneous ethanol injection therapy for hepatocellular carcinoma, results in 136 patients. Am J Roentgenol, 160, 1023-1028.
[30] Redvanly, R. D., Chezmar, J. L., Strauss, R. M., Galloway, J. R., Boyer, T. D., and Bernardino, M. E. (1993). Malignant hepatic tumors, safety of high-dose percutaneous ethanol ablation therapy. Radiology, 188, 283- 285.
[31] Castaneda, F., and Kinne, R. H. K. (2000). Cytotoxicity of milliolar concentrations of ethanol on tumor cell line compared to normal rat hepatocytes in vitro. J Cancer Res Clin Oncol, 126, 505-510.
[32] Castaneda, F., and Kinne, R. H. K. (2001). Apoptosis induced in HepG2 cells by short exposure to millimolar concentrations of ethanol involves the Fas-receptor pathway. J Cancer Res Clin Oncol, 127, 418-424.
[33] Nobuaki, N., Eichhorst, S. T., Muller, M., and Krammer, P. H. (2001). Ethanol-induced apoptosis in hepatoma cells proceeds via intracellular Ca+; elevation activation of TLCK-sensitive proteases, and cytochrome c release. Exp Cell Res, 269, 202-213.
[34] Kurose, I., Higuchi, H., Miura, S., Saito, H., Watanabe, N., et al. (1997). Oxidative stress mediated apoptosis of hepatocytes exposed to acute ethanol intoxication. Hepatology, 25, 368-378.
[35] Santamaria, E., Munoz, J., Fernandez-Irigoyen, J., Prieto, J., and Corrales, F. J. (2007). Toward the discovery of new biomarkers of hepatocellular carcinoma by proteomics. Liver Int, 27, 163-173.
[36] Feng, J. T., Shang, S., and Beretta, L. (2006). Proteomics for the early detection and treatment of hepatocellular carcinoma. Oncogene, 25, 2810-2817.
[37] Chignard, N., and Beretta, L. (2004). Proteomics for hepatocellular carcinoma marker discovery. Gastroenterology, 127, 120-125.
[38] Guo, L., Eisenman, J. R., Mahomkar, R. M., Peschon, J. J., Paxton, R. J., et al. (2002). A proteomic approach for the identification of cell-surface proteins shed by metalloproteases. Mol cell proteomics, 1, 30-36.
[39] Falini, B., and Mason, D. Y. (2002). Protein encoded by genes involved in chromosomal alterations in lymphoma and leukemia, clinical value their detection by immunocytochemistry. Blood, 99, 409-426.
[40] Tanke, H. J., Dirks, R. W., and Raap, T. (2005). FISH and immunocytochemistry, towards visualising single target molecules in living cells. Curr Opin Biotechnol, 16, 49-54.
[41] Mizejewski, G. J. (2001). Alpha-fetoprotein structure and function, relevance to isoforms, epitopes, and conformational variants. Exp Biol Med, 226, 377-408.
[42] Dudich, E., Semenkova, L., Gorbatova, E., Dudich, I., Khromykh, L., et al. (1998). Growth-regulative activity of human alpha-fetoprotein for different types of tumor and normal cells. Tumour Biol, 19, 30-40.
[43] Li, M. S., Ma, Q. L., Chen, Q., Liu, X. H., Li, P. F., et al. (2005). Alphafetoprotein triggers hepatoma cells escaping from immune surveillance through altering the expression of Fas/FasL and tumor necrosis factor related apoptosis-inducing ligand and its receptor of lymphocytes and liver cancer cells. World J Gastroenterol, 11, 2564-2569.
[44] Walczak, H., and Krammer, P. H. (2000). The CD95 (APO-1/Fas) and the TRAIL(APO-2L) Apoptosis systems. Exp Cell Res, 256, 58-66.
[45] Altierti, D. C. (2003). Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene, 22, 8581-8589.
[46] Duffy, M. J., O-Donovan, N., Brennan, D. J., Gallagher, W. M., and Ryan, B. M. (2007). Survivin, a promising tumor biomarker. Cancer lett, 249, 49-60.
[47] Chious, S. K., Jones, M. K., and Tarnawski, A. S. (2003). Survivin - an anti-apoptosis protein, its biological roles and implications for cancer and beyond. Med Sci Monit, 9, 125-129.
[48] Conway, E. M., Pollefeyt, S., Steiner-Mosonyi, M., Luo, W., Devriese, A., et al. (2002). Deficiency of survivin in transgenic mice exacerbates Fas-induced apoptosis via mitochondrial pathway. Gastroenterology, 123, 619-631.
[49] Sah, N. K., Khan, Z., Khan, G. J., and Bisen, P. S. (2006). Structural, functional and therapeutic biology of survivin. Cancer Lett, 244, 166- 171.